1. How does Genzyme’s focus on orphan drugs affect the degree of competition it faces? How does it affect the bargaining power of customers? For a drug to qualify as an ‘orphan drug’‚ a disease must only afflict less than 200‚000 people worldwide. From this we can understand that Genzyme’s target market is a very small niche and consequently there is very little competition. Big pharmaceuticals primarily focus their resources on ‘blockbuster’ drugs because there is a large market to target. Since
Premium Orphan drug Clinical trial Drug discovery
has affected. The plight of the orphan is singular and unique to each individual; however‚ in some cases there are geographical‚ political‚ cultural and/or other variable factors that affect very large populations of orphans‚ sometimes unilaterally. This appears to be the case for orphaned children living in sub-Saharan Africa. Geographically‚ sub-Saharan Africa consists of all the countries located south of the Saharan dessert in the continent of Africa. Orphans living in this area of the continent
Premium Africa AIDS HIV
A FUNDING PROPOSAL TO CREATE HIV\AIDS AWARENESS AND HIV DEATH REDUCTION IN DAYSTAR UNIVERSITY COMMUNITY- MAVOKO CONSTITUENCY‚ EASTERN PROVINCE KENYA. DAYSTAR UNIVERSITY ATHIRIVER CAMPUS RESEARCH DONE AND COMPILED BY: FIONA J. KIPROP 0720- 818697 fifikip@yahoo.com KAREN NJAGI 0701-216017 karenwangui628@gmail.com A FUNDING PROPOSAL TO CREATE HIV\AIDS AWARENESS AND HIV DEATH REDUCTION IN DAYSTAR
Premium Health care AIDS Economics
affects the population of a nation negatively in terms of loss of human lives or massive harm or injury to a large section of the population. In the year 1999‚ former president Daniel Arap Moi declared HIV/AIDS a national disaster in Kenya and called for the establishment of the National AIDS Control Council. HIV is a virus which causes progressive deterioration of the human immune system subjecting the patient to opportunistic diseases such as pneumonia and tuberculosis. The virus is transmitted
Premium AIDS
the United States‚ or less than 5 per 10‚000 individuals in the European Union (Mary‚ 2008). Since 1983‚ the congress of the Orphan Drug law has allowed the companies to own a seven-year monopoly for bringing a new treatment for a rare disease to the market. Marion Finkel‚ former head of the U.S. Food and Drug Administration (FDA)’s Office of New Drug Evaluation said the Orphan drug law was aimed to make products available for patients who had rare diseases. The 1979 report wrote these treatments as
Premium Drug discovery Orphan drug Poverty
been found to be effective in the treatment of acquired immune deficiency syndrom (AIDS) and human immunodeficiency virus (HIV). After careful review of the data and the case I have come up with the recommendation for the company to maintain the current price of Retrovir. Background: Burroughs Wellcome Company produced a drug that proved to be the number one treatment of acquired immune deficiency syndrome (AIDS) in 1987. The company has been pressured to reduce the price of Retrovir when it had
Premium AIDS Immune system Antiretroviral drug
These days‚ the AIDS/ HIV epidemic is one of the most lethal health crises. As yet‚ there were 22 million people died‚ 42 million of people are infected by AIDS. Although professionals nowadays have discovered vaccine for AIDS/ HIV‚ but there still will be over 40 million people would die because of HIV. In many countries especially Africa‚ AIDS epidemic is spreading seriously bringing illness‚ death‚ suffer and poverty. The epidemic has obligated a heavy burden on families‚ communities and economies
Premium Africa Family AIDS
INTRODUCTION The spread of HIV/AIDS is different from that of other epidemics that have occurred in human history‚ owing to the fact that it touches sexual behavior and death‚ and remains hidden for much of the time. The latency period for HIV to reach full blown AIDS on average is 10 years‚ and patients need long-term care and support. Mode of spread of the disease is another factor that makes it different from other recent diseases. Globally‚ an estimated 38.6 (33.4-46.0) million people worldwide
Premium Africa AIDS HIV
Burroughs Wellcome Company‚ Case 6 In 1982‚ the Center for Disease Control and Prevention (CDCP) labeled the acquired immune deficiency syndrome (AIDS) and began to warn the public of the disease. In 1983 and 1984‚ the virus that causes AIDS was isolated and in 1988 it was named the human immunodeficiency virus (HIV). Burroughs Wellcome Company is a subsidiary of Wellcome PLC. Wellcome PLC is a pharmaceutical firm that employs 20‚000 people in 18 countries. Wellcome PLC produces both ethical
Premium HIV AIDS Drug discovery
------------------------------------------------- Top of Form Bottom of Form IFAD strategy paper on HIV/AIDS for East and Southern Africa IFAD strategy paper on HIV/AIDS for East and Southern Africa A. Assessing the Impact of HIV/AIDS on IFAD-Supported Projects 34. This section looks at the relevance of HIV/AIDS to agricultural and rural development projects‚ considering the vulnerability of project target groups and IFAD project staff and their families to HIV/AIDS; the reduced project implementation capacity resulting from the epidemic;
Premium AIDS HIV Tuberculosis